Postoperative inflammation following ocular surgery

Indication for Rimexolone

Population group: Suitable for both men and women, only adults (18 years old or older)

Rimexolone is indicated for the treatment of postoperative inflammation following ocular surgery, for the treatment of anterior uveitis, and for the treatment of corticosteroid responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. The inflammation should be of a noninfectious nature. In more serious cases, and if the posterior part of the globe is affected, subconjunctival injection or systemic treatment is recommended.

For this indication, competent medicine agencies globally authorize below treatments:

4 drops in 4 divided doses daily

Route of admnistration

Ophthalmic

Defined daily dose

4 - 4 {drops}

Dosage regimen

From 1 To 1 {drops} 4 time(s) per day every day

Detailed description

Apply one drop of rimexolone into the conjunctival sac of the affected eye four times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period. There are no clinical data on the use of rimexolone immediately after surgery.

Active ingredient

Rimexolone is a corticosteroid drug. Placebo controlled clinical studies demonstrated that rimexolone is efficacious for the treatment of anterior chamber inflammation following cataract surgery.

Read more about Rimexolone

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner